H.C. Wainwright Boosts Intellia (NTLA) Price Target After MAGNITUDE-2 Hold Lifted

Sheryar Siddiq

Sun, February 15, 2026 at 10:41 PM GMT+9 1 min read

In this article:

NTLA

+2.15%

Intellia Therapeutics, Inc. (NASDAQ:NTLA) ranks among the best innovative stocks to buy according to Wall Street analysts. H.C. Wainwright reiterated a Buy rating on Intellia Therapeutics, Inc. (NASDAQ:NTLA) while boosting its price target to $25 from $15 on January 28, following the removal of a clinical hold on the company’s MAGNITUDE-2 study.

Pixabay/Public Domain

The updated protocol raises the target enrollment to around 60 patients from the originally intended 50, implying a focus on improving risk mitigation and data comprehension rather than discontinuing the drug altogether.

H.C. Wainwright highlighted that the safety incidents that triggered the hold were uncommon, with two Grade 4/5 liver incidents, one of which was fatal, occurring in about 450 treated patients, accounting for less than 0.5% of the group.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a biotech company at the forefront of CRISPR-Cas9 gene-editing technology, developing cutting-edge treatments for both in vivo and ex vivo applications. Its main initiative, NTLA-2001, aims to treat transthyretin amyloidosis, an incurable disease.

While we acknowledge the potential of NTLA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

**READ NEXT: 10 Best Magic Formula Stocks for 2025 and **10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.

Terms and Privacy Policy

Privacy Dashboard

More Info